Indications for OMNIPAQUE ORAL SOLUTION 9:
In conjunction with Omnipaque 240 or 300 intravenous injection, for computerized tomography (CT) of the abdomen.
For oral use only. Give all at once or over a period of up to 45mins. 500–1000mL. See full labeling for concomitant Omnipaque 300 IV inj dosing.
For oral use only. Give all at once or over a period of up to 45mins. 180–750mL. Max oral iodine (<3yrs): 5g; (3–18yrs): 10g. See full labeling for concomitant Omnipaque 240 or 300 IV inj dosing.
OMNIPAQUE ORAL SOLUTION 9 Contraindications:
OMNIPAQUE ORAL SOLUTION 9 Warnings/Precautions:
Hemolysis may occur if administer intravascularly. Have emergency treatment and trained personnel readily available. Monitor for hypersensitivity reactions. Ensure adequate hydration. Elderly. Pregnancy. Nursing mothers: bottle feeding may be substituted for breastfeeding, for 10hrs after administration.
OMNIPAQUE ORAL SOLUTION 9 Classification:
Radiographic contrast medium.
OMNIPAQUE ORAL SOLUTION 9 Interactions:
See full labeling. Concomitant drugs that lower seizure threshold (eg, phenothiazines): not recommended with intrathecal use. Discontinue metformin at time of, or prior to Omnipaque in patients with eGFR 30–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart metformin if renally stable. Increased risk of kidney injury with concomitant nephrotoxic drugs or diuretics. Discontinue CNS active drugs (eg, MAOIs, tricyclics, CNS stimulants, analeptics, tranquilizers, antipsychotics) ≥48hrs before myelography and for ≥24hrs post-procedure. Caution with beta-blockers. May interfere with thyroid uptake of radioactive iodine and decrease efficacy in thyroid carcinoma for up to 6–8 weeks. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.
Oral soln (500mL)—10